Cholestatic jaundice induced by duloxetine in a patient with major depressive disorder

Young Min Park, Bun Hee Lee, Heon Jeong Lee, Seung Gul Kang

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


Duloxetine is a balanced and potent serotonin and noradrenaline reuptake inhibitor (SNRI) and has adverse effects that are commonly associated with such drugs, including nausea, dry mouth, constipation, insomnia, and dizziness. Recently, duloxetine-induced liver injury has also been observed in patients with preexisting liver disease or chronic alcohol use. We investigated the effects of duloxetine in a healthy young adult with major depressive disorder (MDD) but no risk factors, and found that his total bilirubin level increased to 3.3 mg/dL and he developed jaundice after 5 months of duloxetine treatment. Discontinuation of duloxetine treatment saw his total bilirubin level decrease to 1.8 mg/dL. Thus, the administration of duloxetine might induce liver injury in a patient with MDD. However, the limitations of this single case report must be acknowledged. Although the cause of hepatic dysfunction in this case remains to be elucidated, clinicians should monitor liver function carefully after duloxetine treatment. Further investigations with a larger sample are needed.

Original languageEnglish
Pages (from-to)228-230
Number of pages3
JournalPsychiatry Investigation
Issue number3
Publication statusPublished - 2010 Sept


  • Duloxetine
  • Hepatic dysfunction
  • Hepatotoxicity
  • Liver injury
  • Major depressive disorder

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Cholestatic jaundice induced by duloxetine in a patient with major depressive disorder'. Together they form a unique fingerprint.

Cite this